Blog

1) AI Moves From Hype to Healthcare Infrastructure at JPM 2026AI is now treated as core infrastructure across R&amp;D, diagnostics, revenue cycle, and ops, not a side-show.​ Investors are rewarding AI platforms with clear ROI, interoperability and payer alignment, rather than generic point solutions.​ 2) Oncology, Neuro and Heme Dominate the JPM 2026 Deal PipelineConference agendas and guides flag late‑stage oncology, neuropsychiatry/neurology and hematology as the key therapeutic hotspots.​ Many licensing and BD conversations are expected to cluster around biomarker‑linked, companion‑diagnostic enabled assets in these areas.​ 3) Capital Discipline Rules: Fewer, Bigger, De‑Risked Rounds Shape 2026 Narratives2025 data show VC dollars skewing to larger, later‑stage financings with falling deal counts but resilient capital deployment.​ JPM 2026 is framed as a year where investors prioritize clinical proof, regulatory readiness and line‑of‑sight to profitability.​ 4) Medtech and Digital Health Face a ‘Proof Over Promise’ MomentMedtech and digital health sessions emphasize profitability, unit economics and evidence of scale, not growth at any cost.​ Investors are gravitating toward device‑plus‑software, monitoring and real‑world data platforms with defensible data moats.​ 5) IPO Window Narrow, M&amp;A and Take Privates Back at Center StageReports highlight a thin IPO window with a small cohort of scaled, profitable issuers testing public appetite.​ Expectations point to increased tuck‑in M&amp;A, roll‑ups and take‑privates, particularly to add AI and data capabilities.​ 6) Corporate Venture and Strategics Reassert Themselves in 2026 DealmakingCorporate venture arms at large strategics are stepping up to secure early exposure to robotics, diagnostics and AI infrastructure.​ At JPM 2026, strategics are positioned as key partners for later‑stage rounds, platform validation and cross‑border scale‑up.​ 7) Regulators, Payors and AI Governance Take the Main StagePolicy and regulation panels around FDA AI/ML frameworks, privacy, and reimbursement have moved into the conference mainstream.​ Algorithmic bias, explainability and real‑world performance metrics are becoming gating items for both approvals and funding.​ 8) Health Systems Pivot to Care‑Anywhere Models Under Margin PressureProviders arrive at JPM focused on shifting volume to outpatient, home and virtual settings to manage cost and workforce strain.​ AI and automation, combined with new contracting models, underpin many of the health‑system strategy stories told during the week.​ 9) TechBio and Compute‑First Platforms Redefine Biotech’s Next WaveSide forums such as TechBio and AI‑driven showcases spotlight computational biology, AI‑enabled discovery and platform plays.​ Investors increasingly frame these as infrastructure bets that can feed multiple therapeutic programs and partnerships.​ 10) JPM 2026 Marks a Tentative Turn From Survival Mode to Selective GrowthIndustry outlooks suggest 2026 could be a stronger year than the recent downturn, with cautious optimism in biopharma and medtech.​ The week is positioned as a “clearing event,” where high‑quality, de‑risked platforms reset valuations and reopen selective growth pathways.

JP Morgan Healthcare Conference 2026: 10 Potential Headlines and Key Talking Points

Most advanced capitalist economies adopted strong public or “socialised” health systems because broad access to care turned out to be economically useful, politically popular and more efficient than relying mainly on private markets for a complex, high‑cost risk like illness.​Clarifying the premise Almost all high‑income countries combine capitalist product and labour markets with universal or near‑universal health coverage financed largely through taxes or mandatory insurance, rather than pure state‑run “socialist” systems.​Within the OECD, government or compulsory schemes usually account for 70–90% of health spending, even where delivery is mixed public–private.​ Economic reasons Health care has classic market failures: information asymmetry, emergency demand, and huge cost uncertainty, making standard consumer markets bad at pooling risk and ensuring access.​ Comparative OECD analysis finds no evidence that shifting from public to privately dominated financing improves efficiency, while higher public shares of financing are associated with higher system‑wide efficiency on average.​ Historical and political reasons Modern welfare states grew out of industrialisation and social conflict; Bismarck‑era social insurance and later post‑war reforms extended sickness insurance and health services to workers to stabilise capitalist societies and undercut radical movements.​ After the Second World War, many European governments used tax‑funded universal health systems (for example, the NHS in the UK and Sécurité sociale in France) to cement social solidarity and rebuild legitimacy, not to abolish markets more broadly.​ Business and productivity reasons A healthy workforce raises productivity and labour supply, so capital‑owning and centrist parties often accepted public health coverage as a way to support growth while leaving most of the rest of the economy to market forces.​ In systems with employer‑based or fragmented private coverage, like the US, high costs and gaps in coverage are now seen by many firms as a competitiveness problem, reinforcing arguments that universal coverage is compatible with, and even supportive of, capitalism.​ Why the US looks different The US is the main outlier because it locked in employer‑based private insurance during the mid‑20th century and has unusually powerful health‑industry interests, which raises the political cost of shifting to a more socialised model, despite already high public spending.​ Even there, large tax‑funded programs such as Medicare, Medicaid, and the VA mean a substantial share of US health care is already publicly financed, showing the same underlying logic at work.

Why do most capitalist economies have socialist health care systems?

Founders can maximise shareholder value heading into 2026 by building capital efficient, evidence led businesses that are strategically positioned for a consolidation heavy exit market rather than an IPO.​1. Design for M&amp;AAssume your most likely liquidity event is a strategic or sponsor-led acquisition rather than a listing; most digital health and MedTech exits in 2025 are via M&amp;A, with IPOs still subdued.​ Map 5–10 “natural acquirers” and align roadmap, data assets, and geography with their portfolio gaps and roll‑up theses, as PE &nbsp;and VC backed platforms increasingly pursue consolidation plays.​ 2. Prove hard outcomes and ROIInvestors heading into 2026 are explicitly favouring solutions that show measurable improvements in outcomes, cost, or operational efficiency, not just novel tech.​ Build a small number of high‑quality outcome studies (e.g. reduced length of stay, NNT, avoided admissions) and bake a health‑economic case into every board pack and fundraising narrative.​ 3. Be ruthlessly capital efficient The funding model has shifted to “selective scale”: fewer but larger cheques go to companies that demonstrate capital efficiency and clear paths to profitability.​ Track and manage burn multiple, CAC payback, and time-to-profitability at board level; investors now explicitly reward disciplined cost control and opex leverage in valuations.​ 4. Navigate EU regulation as an edge New frameworks such as MDR/IVDR, the EU HTA Regulation and the European Health Data Space are creating both barriers and defensible moats, reinforcing a flight to quality.​ Invest early in regulatory, data protection, and quality infrastructure so you are “acquisition ready” and can sell regulatory readiness and EHDS compliance as part of the asset.​ 5. Focus on consolidating hot sub‑sectors Consolidation pressure is highest in fragmented segments like diagnostics, imaging, virtual care, women’s health, mental health, home care, and specialty outpatient services, which are priority areas for PE.​Position as a “must‑own” platform in a narrowly defined niche rather than a generalist; depth in one consolidation theme typically commands better multiples.​ 6. Build a data and AI moat, not just features Investors and acquirers are favouring AI‑enabled solutions with proprietary data sets and workflow‑embedded models, especially in diagnostics, imaging, and personalised medicine.​ Treat data architecture, interoperability, and model performance as core IP, ensuring ownership and rights to use and commercialise datasets are clean for diligence.​ 7. Professionalise governance and reporting Strong governance, clean cap tables, and high‑quality financial and clinical reporting are now non‑negotiable for value-maximising exits.​ Move early to institutional‑grade board packs: monthly KPI dashboards, cohort economics, regulatory risk registers, and ESG metrics that match healthcare PE and corporate buyer expectations.​ 8. Optimise equity and dilution In a market of larger, less frequent rounds, poor dilution management can erase founder and early shareholder upside even if the exit headline looks strong.​ Model multiple financing and secondary scenarios, use structured rounds sparingly, and align option pools and vesting so key talent is still meaningfully incentivised at exit.​ 9. Play offense on portfolio and geography Large strategics and sponsors are actively pruning portfolios and seeking carve‑outs and cross‑border platform plays across Europe.​ Consider disciplined tuck‑in acquisitions or partnerships to secure missing capabilities or key geographies, making your platform more attractive to roll‑up buyers.​ 10. Tell a 2026 ready equity story Shareholder value in 2026 will accrue disproportionately to companies that combine credible growth, clear profitability path, regulatory readiness, and a role in major thematic trends (AI, outpatient shift, home care, women’s health, electric medicine).​ Refresh your narrative around these themes, anchor it in data, and ensure every investor and strategic conversation connects your company directly to where healthcare capital is actually flowing in 2026.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener">lloyd@nelsonadvisors.co.uk</a>

Maximising shareholder value: 10 Tips for European HealthTech and MedTech founders heading into 2026

Nelson Advisors featured on the HLTH Europe 2026: ‘Step Outside’, the call to action for HLTH Europe 2026: an invitation to leave comfort zones, see challenges differently, and find energy in collaboration and diversity.The Exit Factor: Why M&amp;A is on the rise in healthtechForget IPOs, Europe’s healthtech founders are finding their happily-ever-after in M&amp;A.&nbsp;Corporates want fresh tech, investors want liquidity, and the cheques are getting bigger.&nbsp;By mid-2025 healthcare deal value had soared 87% to €31.8 billion, even as deal count slid 8% according to Nelson Advisors. In the UK, 168 healthtech exits landed by the end of 2024 against just 61 failures. Exits are no longer plan B, they are the headline act.Source: <a href="https://europe.hlth.com/agenda" data-mce-href="https://europe.hlth.com/agenda">https://europe.hlth.com/agenda</a>HLTH Europe is the continent’s #1 healthcare innovation event. Following an enormously successful launch and the exponential growth of HLTH in the US, this landmark event is where global expertise meets local insight to address Europe's unique healthcare challenges and opportunities.About HLTH EuropeAt HLTH, we believe in the power of community to solve health's most pressing issues. We do not accept the status quo and challenge other leaders to do the same. We are proud to run the world’s most important events on health innovation. &nbsp; &nbsp;Building on our track record running the US’s best health events, we brought the HLTH DNA to Europe. World-class speakers, immersive attendee experiences, incredible networking events and parties, and impactful networking programmes are at the heart of HLTH.<a href="https://europe.hlth.com/about-hlth-europe" data-mce-href="https://europe.hlth.com/about-hlth-europe">https://europe.hlth.com/about-hlth-europe</a>

Nelson Advisors featured on the HLTH Europe 2026 Agenda

Nelson Advisors featured in the Deloitte Center for Health Solutions '2026 US Health Care Outlook' Report: Three critical strategies shaping a more resilient, technology-enabled future.Build integrated digital platforms, not one-off digital toolsMore than half of surveyed health plan executives (53%) intend to invest in initiatives that expand the use of digital tools for member engagement and behavior change, and 50% of health system executives plan investments in tech-enabled patient engagement and monitoring tools. Rather than investing in disconnected solutions, however, organizations should consider trying to create or join digital platforms with shared capabilities, data, and governance. (8) Digital platforms are intended to serve as central hubs that connect various health care tools like electronic health records, virtual care, health monitoring apps, and online pharmacy and lab portals with the data they generate, such as patient records, lab results, and medication information.Source: <a href="https://www.deloitte.com/us/en/insights/industry/health-care/life-sciences-and-health-care-industry-outlooks/2026-us-health-care-executive-outlook.html" data-mce-href="https://www.deloitte.com/us/en/insights/industry/health-care/life-sciences-and-health-care-industry-outlooks/2026-us-health-care-executive-outlook.html">https://www.deloitte.com/us/en/insights/industry/health-care/life-sciences-and-health-care-industry-outlooks/2026-us-health-care-executive-outlook.html</a>The Deloitte Center for Health Solutions surveyed 120 C-suite executives (including senior vice presidents and vice presidents) from large US health systems and health plans between August and September 2025. The organizations represented include multihospital systems, independent hospitals, academic medical centers, public health authorities, and a range of health plans (national, provider-sponsored, and regional or Blue Cross and Blue Shield–affiliated), each with annual revenues over US$500 million. The survey aimed to identify the key trends executives expect will shape their organizations’ strategies in 2026 and to learn what actions they plan to take in response.

Nelson Advisors featured in the Deloitte '2026 US Health Care Outlook' Report

European HealthTech this week is centred on EHDS data‑sharing rules, EU‑level digital health funding, and continued AI‑heavy startup investment across the continent. UK NHS digital programmes and EU grant schemes are also shaping demand signals for virtual care, AI triage, and infrastructure plays going into 2026.​EHDS and data governanceThe European Health Data Space Regulation, entering into force in 2025, creates a common framework for primary and secondary use of health data, with phased milestones from 2025–2029 for cross‑border exchange and secondary research use.​Member States must stand up National Digital Health Authorities and Health Data Access Bodies, enabling federated access via HealthData@EU and opening new opportunities for AI, RWE and digital therapeutics vendors.​EU digital health strategy and eventsRecent EU communications highlight that all Member States now provide some form of electronic health record access, with accelerated investment in e‑prescriptions, AI integration and digital governance to boost productivity and resilience.​High‑profile European digital health summits have focused on EHDS, cross‑border EHR interoperability and “One Health” data strategies, underlining that rules and governance, not core technology, are now the main bottleneck for scale.​UK NHS digital and virtual careA new UK reference guide from NHS Confed and national digital programmes outlines up to £10 billion in NHS technology and digital transformation spending by 2028/29, with priorities around the NHS App, virtual wards and AI infrastructure.​The NHS App is being positioned as the single gateway to services, with integration of wearables, remote monitoring and AI‑powered advice/triage tools, creating a favourable environment for UK‑ and Europe‑focused HealthTech vendors.​Funding, grants and AI focusEU programmes such as EU4Health and Digital Europe have earmarked substantial digital health funding, particularly for AI, interoperability, cybersecurity and cross‑border infrastructure, often blended with VC rounds as non‑dilutive capital.​2025 funding analyses show multi‑billion‑euro HealthTech capital deployment in Europe, with a clear tilt toward AI‑driven ventures and infrastructure (data platforms, workflow tools), supported by reimbursement schemes like DiGA and similar national models.Ecosystem initiatives and callsEIT Health’s 2025 “Digital Transformation of Healthcare” flagship call is steering funding into patient‑centred digital health solutions and evidence generation for CE‑marked digital medical devices entering EU markets.​EU‑backed projects such as DigitalHealthEurope and related EHDS implementation initiatives continue to feed standards and policy recommendations, shaping market access conditions for HealthTech vendors across Member States&gt;&gt;&gt;European MedTech this week is dominated by MDR/IVDR regulatory moves around EUDAMED, EU innovation/health packages, and continued capital formation for MedTech and digital health scale‑ups heading into 2026. Imaging, AI platforms, and late‑stage MedTech funding vehicles remain key themes, with Europe‑focused co‑investment structures and hospital‑facing workflow innovation in focus.​Regulation and MDR/IVDR movesThe European Commission is progressing a broader health and innovation package that includes targeted simplification of MDR/IVDR, aiming for a more efficient and predictable system for device approvals.​A central element is phased mandatory application of EUDAMED modules, tightening post‑market surveillance, vigilance and economic operator registration, while still trying to avoid supply disruptions for legacy devices.​EUDAMED and legacy timelinesFrom 2025, Regulation (EU) 2024/1860 introduces new information obligations, stepwise activation of EUDAMED modules, and extended transition periods for many legacy devices and IVDs.​Legacy IVDs can now stay on the market up to 2027–2029 depending on risk class, while many higher‑risk legacy devices under MDD/AIMDD have transition windows to 2027–2028, easing near‑term cliff‑edge risks for manufacturers.​Capital formation and fundingA €150 million co‑investment vehicle between the European Investment Bank and Angelini Ventures (€75 million each) is being finalised to support 7–10 European biotech, MedTech and digital health companies at market‑launch/scale‑up stage.​ Broader 2025 analyses show multi‑billion‑euro healthtech funding in Europe, with most recent capital flowing into AI‑driven ventures and digital infrastructure, supported by EHDS‑aligned policies and national reimbursement schemes such as DiGA‑style frameworks.​ Market and M&amp;A signals Commentators tracking 2025 MedTech dealflow note ongoing strategic consolidation, particularly in areas like ophthalmology clinics and robotics, as platforms seek pan‑European scale and integrated care models.​There is a visible tilt toward later‑stage, infrastructure‑heavy assets and imaging/diagnostics software, as hospital buyers prioritise workflow integration and data platforms over point solutions.​Imaging, AI and hospital ITEuropean majors such as Siemens Healthineers and Philips are pushing next‑generation MRI/CT with deeply embedded AI and energy‑efficiency features, reinforcing Europe’s strength in high‑end imaging systems plus software.​Consolidation in imaging IT (e.g., large‑cap acquisitions of PACS/VNA and advanced imaging software vendors) is reshaping the competitive landscape in EU hospitals, intensifying rivalry with incumbents like Agfa and Sectra on enterprise imaging platforms.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email<a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title=" lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary"> lloyd@nelsonadvisors.co.uk</a>

Nelson Advisors

Blog

JP Morgan Healthcare Conference 2026: 10 Potential Headli...

Why do most capitalist economies have socialist health ca...

Maximising shareholder value: 10 Tips for European Health...

Nelson Advisors featured on the HLTH Europe 2026 Agenda

Nelson Advisors featured in the Deloitte '2026 US Health ...

This Week in European HealthTech and MedTech: 30th Decemb...